Nonmyeloablative allogeneic stem-cell transplantation for malignancy

BlueCross BlueShield Association
Record ID 32003000739
Authors' objectives:

This Assessment reviews the available evidence to determine whether, compared with the established alternatives, nonmyeloablative allogeneic stem-cell transplantation improves the net health outcome of three patient groups:

- those with chronic myeloid leukemia, acute lymphocytic or myeloid leukemia, Hodgkin's disease, or non-Hodgkin's lymphoma who are ineligible for conventional high-dose chemotherapy (HDC) or allogeneic transplantation of stem cells (alloSCT) because of advanced age, poor organ function, or comorbid conditions;

- those with multiple myeloma or other hematologic malignancies for which evidence on the outcomes of conventional HDC/alloSCT is insufficient to permit conclusions; and

- those with renal cancer or other tumors of solid tissues or organs.

Authors' methods: Systematic review
Project Status: Completed
Year Published: 2001
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: United States
MeSH Terms
  • Hematopoietic Stem Cell Transplantation
  • Hodgkin Disease
  • Leukemia, Lymphoid
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Leukemia, Myeloid
  • Lymphoma, Non-Hodgkin
  • Stem Cells
  • Transplantation
Organisation Name: BlueCross BlueShield Association
Contact Address: BlueCross BlueShield Association, Technology Evaluation Center, 225 North Michigan Ave, Chicago, Illinois, USA. Tel: 888 832 4321
Contact Name:
Contact Email:
Copyright: BlueCross BlueShield Association (BCBS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.